SOLID TUMOR

This early-phase study tests a new treatment called GC203 TIL for people with advanced solid tumors (cancers in organs like the breast, lung, or gut) that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to bet…

This study tests whether a year-long maintenance treatment with sirolimus and low-dose chemotherapy can help prevent cancer from coming back in children and young adults (ages 1 to 30) with high-risk solid tumors. Participants take daily sirolimus and twice-daily celecoxib along …

This study tests a new oral drug, TNG456, in people with advanced solid tumors that have lost a gene called MTAP. The drug works by blocking a protein (PRMT5) that these tumors need to grow. The study has two parts: first, finding the safest dose of TNG456 alone or with abemacicl…

This study tests pembrolizumab, an immunotherapy that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to treatment. The goal is to see if the drug can shrink …

This early-phase study tests a new approach called peptide alarm therapy (PAT) given as an injection directly into tumors, along with a standard immunotherapy drug, for people with advanced solid tumors that have stopped responding to at least one prior treatment. The goal is to …

This early-phase study tests a new drug called BL-B01D1 in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 36 adults aged 18 to 75 will take part.

This early-phase study tests a new drug called GNC-077 in about 20 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants must …

This study tests a new drug called JK06, which is designed to seek out and attack cancer cells while sparing healthy ones. It is for adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the safest dose and see if the drug …

This study tests a drug called KN035 in people with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). About 200 participants whose cancer has not responded to standard treatments will receive KN035 alone. The main goal is to see if the drug can shrink tumo…

This study tests a new drug called SHR-9839 combined with other anti-tumor treatments for people with advanced solid tumors. The goal is to see if the combination is safe and helps shrink or control tumors. About 70 adults aged 18-70 with measurable tumors and good performance st…

This study tests a new drug called HYP-6589 in people with advanced solid tumors or a type of lung cancer (NSCLC) with specific gene changes. The drug is given alone or with other cancer drugs. The goal is to see if it is safe and helps shrink tumors. About 115 adults aged 18 to …

This study tests a new drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, ovarian, lung, head and neck, esophageal, or cervical cancer) that have specific changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and shrinks tu…

This early-phase study tests a new drug called PT0511 in about 195 adults with advanced solid tumors that have a KRAS mutation or amplification, including colorectal, pancreatic, and lung cancers. The main goals are to check safety, find the best dose, and see how the drug works …

This study tests an experimental pill called IPN01194 in adults with advanced solid tumors (cancers that have spread). The goal is to find the right dose and see if it is safe and can shrink tumors. About 220 people with specific genetic mutations will take the drug by mouth. Thi…

This early-phase study tests a virus called VRT106 that is designed to infect and destroy cancer cells. About 30 adults with advanced solid tumors that haven't responded to standard treatments will receive injections directly into their tumors. The main goals are to check safety …

This early-phase study tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose, either alone or combined with chemotherapy. Researchers will also loo…

This early-phase study tests a new drug called BL-B16D1 in 21 adults with head and neck cancer or other solid tumors that have returned or spread. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants must have tried st…

This early-phase study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various solid cancers…

This early-phase study tests a new drug called GNC-077 in 20 adults with advanced breast cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug by injection, …

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in people with advanced bladder cancer or other solid tumors that have not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. About 52…

This study tests a new drug called SHR-7367 combined with other anti-cancer medicines in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 100 adults aged 18-75 with good organ function and at least one meas…

This early-stage study tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors (like kidney, prostate, lung, or colon cancer) that can't be removed by surgery. The main goals are to find safe doses and see if the treatment sh…

This early-phase trial tests a new treatment called CLDN6 CAR-T, which uses a patient's own immune cells to fight solid tumors that have returned or not responded to standard therapy. The treatment targets a protein called CLDN6 found on tumor cells. The study will enroll about 2…

This study is for people with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many tumor cells. The goal is to control the disease and understan…

This early-phase study tests a new drug called BL-M17D1 in people with advanced HER2-positive or low-HER2 gastrointestinal cancers and other solid tumors. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 20 adults will take part, …

This study tests a drug called toripalimab, which helps the immune system fight cancer. It is for adults with advanced solid tumors that have specific gene changes (POLE or POLD-1) but not high microsatellite instability. The goal is to see if the drug can shrink tumors and contr…

This study tests a new drug called YH42946 in people with advanced solid tumors that have certain genetic changes (HER2 or EGFR). The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. About 161 participants will receive the drug, and…

This study tests a new drug called IPG1094 in about 60 adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study has two parts: first, finding a safe dose, the…

This early-phase study tests a new drug called BL-M24D1 in 33 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried other tr…

This study tests an experimental drug called TRK-950, alone or with another drug (nivolumab), in people with advanced solid tumors or melanoma that have not responded to standard treatments. The goal is to check safety, find the right dose, and see if the drug can shrink tumors. …

This study tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy helps people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) w…

This study is testing whether adding bevacizumab to standard chemotherapy before surgery can help shrink tumors in people with early or locally advanced HER2-negative breast cancer. About 75 participants will receive the combination treatment, and researchers will measure how man…

This study tests an experimental drug called BL-B01D1 in 38 people with advanced or recurrent gynecological cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must be 18–75 years old and…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study tests an experimental drug called SAR445877 in about 542 adults with advanced solid tumors that have spread or can't be removed. The goal is to find safe doses and see if the drug, given alone or with other cancer treatments, can shrink tumors. The trial has two parts:…

This early-stage trial tests an experimental drug, MRTX1719, in adults with advanced solid tumors that have a specific genetic change (loss of the MTAP gene). The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants wit…

This early-phase study tests the safety of combining two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. These cancers have not responded to standard treatments. The goal is to find safe doses and understand side effects. Ab…

This study tests a new oral drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults wit…

This study tests an experimental drug called MORAb-202 that delivers chemotherapy directly to cancer cells with a specific marker (FRα). It is for people with ovarian, endometrial, lung, or triple-negative breast cancer that has spread. The goal is to find the safest and most eff…

This early-stage study tests an oral probiotic (R-5780) taken alongside a standard immunotherapy drug (PD-1 inhibitor) in adults with advanced solid tumors like melanoma. The main goal is to see if the combination is safe and tolerable. About 33 participants will be enrolled to a…

This early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. The main goals are to find safe doses and ch…

This study tests a new drug called HRS-4508 in people with advanced non-small cell lung cancer that has not responded to standard treatments. About 120 adults aged 18 to 80 will receive the drug to see if it shrinks tumors and how safe it is. The goal is to control the disease an…

This early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 10…

This early-phase study tests a new drug called BL-M08D1 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. About 22 adults will take part in th…

This study tests an experimental pill called INX-315 in 150 people with advanced cancers, including certain breast and ovarian cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study has three…

This early-phase study tests a new drug called STP938 in adults with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and check how the body processes the drug. A special focus is on ovarian cancers missing a certain gene. About 7…

This early-stage trial tests the safety of a new drug called NP-101 in about 35 adults with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the right dose and check for side effects. It is not a cure, but a step toward better cont…

This early-phase study tests a new drug called GNC-039 in people with advanced solid tumors, including a type of brain cancer called glioma, that have come back or spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 60…

This study tests an experimental drug called SMP-3124LP in 120 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, finding the right dose, then tes…

This study tests a new drug, DR30206, in people with advanced or metastatic solid tumors who have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 216 adults aged 18 to 75 will take pa…

This early-phase trial tests a new drug called BL-M24D1 in about 16 people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of whether the drug shrinks tumors. Participants must…

This study tests two experimental drugs, 7MW3711 and JS207, given together (sometimes with chemo) for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and check for side effects. About 280 adults with goo…

This study tests a new drug called AGX101 in people with advanced solid tumors that have not responded to standard treatments. The drug is given through a vein and aims to shrink or control tumors. The main goals are to find the safest dose and understand side effects. About 80 p…

This early-phase study tests a new drug, SON-DP, in 96 adults with advanced solid tumors, including liver and gastric cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have a measurable tumor and be between 1…

This study tests a new drug called JAB-21822 (Glecirasib) in people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug can shrink tumors and how safe it is. About 88 participants will take the drug daily, …

This early-stage trial tests a new drug called JBZ-001 in about 25 adults with advanced solid tumors or certain lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that t…

This early-phase study tests a new drug called BL-B16D1 in 21 adults with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participant…

This study tests a drug called selinexor in children and young adults whose Wilms tumor or other solid tumors have come back or not responded to treatment. The goal is to see if the drug can shrink or control the tumors. About 45 participants will receive the drug, and doctors wi…

This early-phase study tests whether specially trained immune cells from a donor can safely help children with high-risk solid tumors that have not responded to standard treatments. Up to 36 children with cancers like neuroblastoma or sarcoma will receive infusions of these cells…

This early-phase study tests a new drug called BM230 in people with advanced solid tumors that are linked to HER2. The goal is to find a safe dose and check for side effects. About 123 participants will take part, first in a dose-finding stage, then in a stage that looks more clo…

This early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people with cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). About 32 adults with solid tumors or high-grade gliomas will receive the com…

This study tests a new treatment called QH101 for people with blood cancers or solid tumors that have not responded to standard therapies. QH101 uses specially engineered immune cells from a donor to better recognize and kill cancer cells while lasting longer in the body. The tri…

This study is testing an experimental drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that have not responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow …

This study is testing a combination of two drugs, AL8326 and toripalimab, in people with advanced solid tumors that have stopped responding to standard therapy or have no effective treatment options. The goal is to find the best dose and see if the combination can shrink tumors. …

This early-phase study tests a new drug called OCT-598 in about 51 adults with advanced solid tumors (breast, lung, prostate, head/neck, or stomach cancer). The main goal is to find the safest dose and check for side effects when given alone or with standard treatments. Participa…

This early-stage trial tests a new drug called CBP-1019 combined with standard chemotherapy (FOLFOX) and possibly other drugs like bevacizumab, pembrolizumab, or enzalutamide. The goal is to find safe doses and see if the combination can shrink or control tumors in people with ad…

This early-stage trial tests a personalized vaccine made from a patient's own tumor. The goal is to see if it's safe and can help the immune system fight advanced solid cancers. About 30 adults with advanced solid tumors who have tried other treatments will receive the vaccine, e…

This early-phase study tests OBT076, a drug that acts like a guided missile: it targets a protein called CD205 found on cancer cells and delivers a powerful anti-cancer drug directly to them. The study enrolls about 200 adults with advanced solid tumors that have come back or spr…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors, including stomach, pancreatic, and bile duct cancers. The main goals are to check the drug's safety, find the best dose, and see how the body process…

This study tests two drugs, VS-6766 and defactinib, in people with certain gynecological cancers that have come back. The goal is to see if the combination can shrink tumors and how safe it is. About 55 adults with specific gene mutations (RAS, BRAF, or NF1) will take part.

This study looks at how well umbilical cord blood stem cells from unrelated donors can restore blood cell counts in people with serious blood cancers, immune deficiencies, or genetic disorders. Researchers will track how often the transplant succeeds, how long it takes for blood …

This study tests a new drug, 177Lu-FAP-2286, that delivers radiation directly to cancer cells in people with advanced solid tumors. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors in pancreatic, lung, and breast cancers, alone…

This early-phase study tests a new drug called GTB-5550 in adults with advanced solid tumors that have not responded to prior treatments. The drug is designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. The main goal is to find the …

This study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment involves two injections given directly into the tumor, one after the other, every two weeks. The goal is to find a safe dose and see if it can shrin…

This study tests a radioactive drug (lutetium Lu 177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the best dose and see if it is safe. About 20 children whose cancer has not responded to prior treatment will t…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help children whose solid tumors have come back or not responded to previous treatment. About 23 children with relapsed/refractory solid tumors, including rhabdomyosarcoma, will recei…

This early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…

This study tests a new drug called BHV-1510, alone or with another cancer drug (cemiplimab), in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors. About 500 adults with incur…

This study tests a new drug called ZGGS34 in about 400 people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and second, checking if the drug works alone or with chemotherapy. Only people whose tumor…

This early-stage study is testing an experimental drug called LB1410 in people with advanced solid tumors or lymphoma that hasn't responded to standard treatments. The drug is a bispecific antibody designed to block two proteins (PD-1 and TIM-3) that can help cancer hide from the…

This early-phase study tests a new drug called BB-1709 in 300 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look at how the drug moves through the body …

This early-stage study tests an experimental oral drug called GIM-531 in people with advanced solid tumors (including stage IV melanoma) that have stopped responding to standard treatments. The drug works by targeting certain immune cells to help the body fight cancer. Researcher…

This early-phase study tests a new drug called BL-M17D1 in about 20 adults with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants…

This early-phase study tests the safety and best dose of a new drug combination (NEROFE and doxorubicin) in adults with advanced solid tumors that have a KRAS mutation and ST2 protein. About 24 participants whose cancer has worsened after standard treatments will receive weekly d…

This early-phase study tests a new drug called TH9619 in people with advanced solid tumors, including colorectal, head and neck, lung, and stomach cancers. The main goal is to find a safe dose and check for side effects. About 43 adults who have already tried at least one standar…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain types of breast cancer, head and neck cancer, or …

This study offers continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were already benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to monitor long-term safety and side effects…

This early-phase study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, and others). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. About 554 …

This early-phase trial tests a new drug, SB17170, in about 50 adults with advanced solid tumors that have stopped responding to standard care. The main goals are to find the safest dose and check for side effects. Researchers will also measure how the drug moves through the body …

This early-phase study tests a new drug called BL-B16D1 in 21 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. Participants receive the drug and…

This early-phase study tests a new drug called JZP815 in adults with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to find a safe dose and see if the drug can shrink tumors. About 332 participants who have tried all other tr…

This study tests a new drug called CUSP06 for people with ovarian cancer or other solid tumors that have stopped responding to standard treatments. The drug works like a guided missile, targeting a protein on cancer cells to deliver a powerful toxin directly. The main goals are t…

This study tests a new drug called JYP0015 in adults with advanced solid tumors that have a specific genetic change called RAS mutation. The goal is to see if the drug is safe and can shrink tumors. About 210 people with pancreatic, lung, or colorectal cancer will take part.

This study tests a new drug, ASP5834, in people with advanced solid tumors that have certain changes in the KRAS gene. The goal is to find a safe dose and check for side effects. Some participants with colorectal cancer will also receive another drug called panitumumab. The study…

This study tests a new treatment called 177Lu-SN201 for people with advanced solid tumors that have not responded to standard therapies. The treatment uses tiny particles that deliver radiation directly to tumors. The goal is to find the safest dose and see if it can shrink tumor…

This study tests a new drug called TL118 in adults whose solid tumors have a specific gene change (NTRK fusion). The goal is to see if the drug can shrink tumors or slow their growth. About 60 people with advanced or spreading cancers that have not responded to other treatments w…

This study tests a new drug, FOG-001, in about 595 people with advanced solid tumors that have not responded to other treatments. The goal is to see if FOG-001 is safe and can shrink tumors or slow their growth. The trial focuses on several cancer types, including colorectal, pro…

This is a first-in-human study testing a new drug called AT03-65 in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and understand side effects. About 83 participants will take part in this early-phase trial.

This study tests two experimental drugs (LB1410 and LB4330) given together to people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink or control tumors. About 194 adults will take part, and the…

This study tests a new drug called HRS-8364 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 282 adults aged 18-75 will participate across multiple hospitals.

This early-phase study tests a new drug called SB-4826 in adults with advanced solid tumors or non-Hodgkin lymphoma. The main goal is to find a safe dose and see if it shrinks tumors. Some lymphoma patients will also get the drug combined with rituximab. Participants take SB-4826…

This study tests a drug called Envafolimab in people with advanced solid tumors that have not responded to standard treatments. The goal is to see how well the drug works in tumors with high genetic mutations (TMB-H) compared to those with low mutations. About 126 adults will tak…

This study tests an experimental drug called BL-B01D1 in 76 adults with advanced urinary system or other solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. Participants will be monitored for side e…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors (including some lung cancers) that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants …

This early-phase study tests a new drug called BHV-1530 in about 95 adults whose solid tumors have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrinks tumors or slows the disea…

This study tests a new drug called MCLA-129 in people with advanced solid tumors like lung, head and neck, or colorectal cancer that has not responded to standard treatments. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met) to b…

This study tests whether a drug called TSR-042, followed by standard chemotherapy and radiation, can shrink or eliminate advanced solid tumors that have a specific genetic flaw (mismatch repair deficiency). About 200 adults with locally advanced tumors that haven't spread will re…

This study tests a combination of two drugs (BL-B01D1 and a PD-1 antibody) in adults with advanced or spreading non-small cell lung cancer, nasopharyngeal cancer, or other solid tumors. The goal is to see if the combo can shrink tumors and control the disease. About 570 participa…

This early-phase study tests an experimental drug called IBI3026 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the safest dose and check for side effects. About 300 participants will take part across multiple cen…

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This early-phase study tests a new drug called EXS74539 in about 40 adults with advanced solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrin…

This early-phase study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with solid tumors that have returned or not responded to treatment. The main goal is to find a safe dose with manageable side effects. The drugs targe…

This early-phase study tests an injectable drug called SHR-A1811(sc) in 107 adults with solid tumors. The goal is to see how the drug moves through the body, check its safety, and look for signs it shrinks tumors. Participants must have advanced cancer and be in fairly good healt…

This early-phase trial tests a new drug called XB628 in about 75 people whose advanced solid tumors have not responded to standard treatments. XB628 is designed to help the body's natural killer cells attack cancer cells more effectively. The main goals are to check safety and fi…

This early safety study is testing a new combination treatment for patients with large, advanced solid tumors that have stopped responding to standard therapies. It combines two types of targeted radiation with an immunotherapy drug called tislelizumab. The main goal is to find o…

This early-phase study tests a new type of immune cell therapy (CAR-T) designed to target a protein called ALPP found on some advanced solid tumors. About 24 adults whose cancers have not responded to standard treatments will receive the therapy to see if it is safe and tolerable…

This early-phase study tests an experimental drug called BGB-26808, either alone or combined with an immunotherapy (tislelizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find the safest and most effective dose…

This early-stage trial tests an experimental drug called IMGS-001 in people with advanced solid tumors that have returned or stopped responding to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in specific cancers like ovarian can…

This early-stage study tests a new drug called PT0253 in about 115 adults whose advanced solid tumors have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Participants must have meas…

This early-phase study tests a new drug, ASP3082, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the best dose, either alone or combined with another drug (cetuximab). About 681 participants w…

This early-stage trial is testing a new drug called GDC-7035 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and combined with other ca…

This early-stage trial is testing a new drug called HY0001a in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose, understand how the drug moves through the body, and see if it shows any early signs of shrinkin…

This early-stage trial is testing the safety of a new two-part treatment for people with advanced HER2-positive solid tumors, such as breast, lung, or gastric cancer. First, a specially designed virus is injected directly into one tumor to help alert the immune system. A few days…

This study tests a new PET scan that uses a special probe to find a protein called CLDN18.2 on solid tumors. The goal is to see if the scan can identify which patients might benefit from treatments that target this protein. About 15 adults with solid tumors will receive an inject…

This study is testing a new type of PET scan that uses a special tracer to find a protein called Trop2 on cancer cells. The goal is to see if this scan can detect and monitor many types of solid tumors more accurately than current methods. About 400 adults with or suspected of ha…

This study tests a new type of PET scan that uses a special tracer to show how much PD-L1 protein is on solid tumors. PD-L1 helps some tumors hide from the immune system. The scan aims to help doctors choose the right treatment, see if treatment is working, and spot early signs o…

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, have trouble sleeping, or are very tired. The program is delivered through telehealth (video or phone calls). Researchers want to see if patients …

This pilot study tests if brodalumab, a drug approved for autoimmune diseases, can safely reduce severe side effects caused by cancer immunotherapy. About 11 adults with various solid tumors who have immune-related side effects will receive brodalumab. The goal is to see if it lo…

This study aims to adapt a counseling approach called Meaning Centered Psychotherapy to better support Latinos with advanced cancer. Researchers will work with 190 participants to see if the culturally tailored program improves spiritual well-being and eases anxiety and depressio…

This study tests a program where nurses start conversations about palliative care early for children with cancer. The goal is to see if this improves the child's quality of life and reduces side effects. About 120 children and their families will take part, with some getting the …

This study adapts a counseling method called Meaning Centered Psychotherapy to better support Latinos with advanced cancer. Researchers want to see if this culturally tailored program can improve quality of life and spiritual well-being. About 285 adults with stage III or IV soli…

This study tests whether a one-day hospital visit that includes medical, psychological, and social support can improve the quality of life for teens and young adults (ages 15-25) who have just finished cancer treatment. About 214 participants will be randomly assigned to receive …

This study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses and patients talk about the patient's health-related values as part of routine cancer care. The goal is to make care more personal and supportive. About 234 adult…

This study looks at whether a program of exercise and psychological support before cancer treatment (called prehabilitation) can improve physical and mental well-being in people with solid tumors, like breast cancer. About 125 participants will either receive this program or stan…

This study looks at whether medical hypnosis can help reduce anxiety in cancer patients who are moderately to very anxious during their radiation treatments. About 45 adults with solid tumors will be randomly assigned to either listen to music or listen to music plus receive hypn…

This study looks at whether a special dye, called Indocyanine Green (ICG), can help surgeons find lymph nodes that might contain cancer during surgery for children with solid tumors in the belly. About 25 children under 21 with Wilms tumor or a type of muscle cancer will get the …

This study looks at the genetic makeup of solid tumors in 5,500 cancer patients to help doctors choose the most suitable treatments and clinical trials. Participants provide a tumor sample for molecular profiling. The goal is to learn how genetic changes relate to treatment outco…

This study follows 940 adults with solid tumors who are starting immunotherapy. Researchers collect blood samples and health data before and during treatment to find early signs of serious side effects, especially those affecting the brain and nerves. The goal is to better predic…

This study aims to safely collect health information from wearable devices (like smartwatches) and other digital tools from up to 3,644 people with solid tumors. Researchers want to see how this data might relate to cancer diagnosis, treatment response, and risk factors. No new t…

This early-phase study tests whether an artificial intelligence platform can personalize cancer treatment for people with solid tumors (like breast or gastrointestinal cancer). Researchers will use a patient's own tumor sample to pick the best drug combination, then an AI system …

This study follows 400 men with solid tumors to understand how cancer care impacts their ability to work and their overall well-being. It focuses on low-income and Latino men, who often face extra challenges. Researchers will track employment hours, mental health, and financial s…

This study aims to see if a new predictive model can accurately tell which patients with melanoma and other skin cancers will respond to immunotherapy. Researchers will collect tumor tissue, blood, and stool samples from 1,000 participants and compare the model's predictions to a…

This study is creating a registry of children, teens, and young adults (ages 1 month to 39 years) who have been diagnosed with a very rare solid tumor within the past year. Researchers will collect medical records, leftover tumor samples for genetic testing, and annual questionna…

This study tests whether cancer patients getting chemotherapy can use an Apple Watch and iPhone app to track their health from home. Researchers want to see if patients will wear the watch most of the day. If successful, this approach could help doctors catch problems early and r…

This study looks at 50 adults with advanced solid tumors that no longer respond to standard treatments. Researchers will use genetic tests to match patients with experimental or off-label therapies, then track how well the tumors shrink and how patients feel. The goal is to creat…

This study tests a new communication tool called 'Let's Get REAL' that helps children and teens (ages 8-17) and their families talk about stem cell transplant and cellular therapy decisions. About 60 youth and their parents will try the tool, and researchers will measure if it is…

This study follows 100 children and young adults who have received CAR T-cell therapy to learn about short- and long-term side effects. Researchers will track how often patients get infections, have delays in blood cell recovery, or experience nerve damage. The goal is to better …

This study aims to understand how the body's immune cells react to a new type of vaccine (neoantigen vaccine) that helps the immune system recognize and fight cancer. Researchers will collect blood samples from 24 people with solid tumors or healthy volunteers to study immune cel…

This study aims to better understand rare solid tumors by collecting biological samples (like blood, saliva, and tumor tissue) and health information from up to 10,000 people over many years. Participants include people with a rare tumor, those with a genetic risk for one, and th…

This study looks at sleep quality and disorders in adults who survived childhood cancer, including leukemia, brain tumors, and solid tumors. Researchers will use questionnaires and home sleep monitors to measure insomnia, sleepiness, and circadian rhythms. The goal is to learn ho…

This study tests if a green dye, called ICG, can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps remove …

This study is testing whether a new radioactive imaging agent can safely and clearly show tumors in people with many types of solid cancers. About 32 adults will receive a single injection of the agent and then have PET/CT scans to see where it goes in the body. The goal is to le…

This study looks at whether a blood test (liquid biopsy) can find genetic changes in tumors to help doctors pick the best treatment for each patient. About 150 adults with solid cancers like breast, lung, or head & neck cancer will give blood samples over time. The goal is to see…

This study aims to find genetic changes in the tumors of 10,000 adults with advanced solid tumors or blood cancers. Researchers will use advanced DNA testing to identify these changes and then try to match patients with early-phase clinical trials of drugs that target those speci…